anti n myc (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
86
Structured Review
Cell Signaling Technology Inc
anti n myc
Anti N Myc, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mycn+antibody/pmc13049659-10-0-4
Average 86 stars, based on 1 article reviews
Anti N Myc, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mycn+antibody/pmc13049659-10-0-4
Average 86 stars, based on 1 article reviews
anti n myc - by Bioz Stars,
2026-09
86/100 stars
Images
Related Articles
Chromatin Immunoprecipitation:Article Title: Mycn deficiency underlies the development of orofacial clefts in mice and humans. Article Snippet: .. ChIP dilution buffer and protein beads was added to the samples and rested on the magnetic rack for 2 min. ChIP dilution (containing 20 μL Immunohistochemistry:Article Title: Multi-omics analysis delineates molecular signatures of spinal ependymal tumor. Article Snippet: .. To confirm the MYCN-status, we performed IHC staining using Article Title: Multi-omics analysis delineates molecular signatures of spinal ependymal tumor Article Snippet: .. To confirm the MYCN -status, we performed IHC staining using Staining:Article Title: Multi-omics analysis delineates molecular signatures of spinal ependymal tumor. Article Snippet: .. To confirm the MYCN-status, we performed IHC staining using Article Title: Multi-omics analysis delineates molecular signatures of spinal ependymal tumor Article Snippet: .. To confirm the MYCN -status, we performed IHC staining using Whole Complete genome sequencing:Article Title: Multi-omics analysis delineates molecular signatures of spinal ependymal tumor. Article Snippet: .. To confirm the MYCN-status, we performed IHC staining using Article Title: Multi-omics analysis delineates molecular signatures of spinal ependymal tumor Article Snippet: .. To confirm the MYCN -status, we performed IHC staining using other:Article Title: MYCN protein stability is a better prognostic indicator in neuroblastoma Article Snippet: Diagnostic tumor samples from the cohort of 71 patients were tested by whole exome sequencing (WES) and FISH at the same time, and those from the cohort of 127 patients were tested by Article Title: Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof Article Snippet: Blots were then incubated for 1 hour at room temperature in secondary antibodies, diluted 1:10,000, and imaged using SuperSignal West chemiluminescent reagents (Life Technologies). Article Title: Kinome reprogramming of G2/M kinases and repression of MYCN contribute to superior efficacy of lorlatinib in ALK-driven neuroblastoma Article Snippet: Page 2 of 31 Mutations in the tyrosine kinase domain of the Anaplastic Lymphoma Kinase (ALK) oncogene in neuroblastoma occur most frequently at one of three hotspot amino acid residues, with the F1174* and F1245* variants conferring de novo resistance to first and second generation ALK inhibitors including crizotinib and ceritinib.. Lorlatinib, a third generation ALK/ROS inhibitor, overcomes de novo resistance and induces complete and sustained tumor regressions in patient-derived xenograft (PDX) models unresponsive to crizotinib.. Lorlatinib has now completed Phase 1 testing in children and adults with relapsed/refractory ALK-driven neuroblastoma and entered pivotal Phase 3 testing within the Children’s Oncology Group. Incubation:Article Title: Ceftriaxone exerts antitumor effects in MYCN ‐driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression Article Snippet: Cells were treated with 25 μ m MG132 (Millipore) in methionine‐free RPMI‐1640 supplemented with 200 μ m l ‐HPG for 2 h and lysed using immunoprecipitation lysis buffer (25 m m Tris–HCl pH 7.4, 150 m m NaCl, 1% NP‐40, 1 m m EDTA, and 5% glycerol) containing protease and phosphatase inhibitors. .. The protein was collected and incubated with Article Title: Ceftriaxone exerts antitumor effects in MYCN-driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression. Article Snippet: Immunoprecipitation Cells were treated with 25 lM MG132 (Millipore) in methionine-free RPMI-1640 supplemented with 200 lM L-HPG for 2 h and lysed using immunoprecipitation lysis buffer (25 mM Tris–HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, and 5% glycerol) containing protease and phosphatase inhibitors. .. The protein was collected and incubated with Control:Article Title: Ceftriaxone exerts antitumor effects in MYCN ‐driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression Article Snippet: Cells were treated with 25 μ m MG132 (Millipore) in methionine‐free RPMI‐1640 supplemented with 200 μ m l ‐HPG for 2 h and lysed using immunoprecipitation lysis buffer (25 m m Tris–HCl pH 7.4, 150 m m NaCl, 1% NP‐40, 1 m m EDTA, and 5% glycerol) containing protease and phosphatase inhibitors. .. The protein was collected and incubated with Article Title: Ceftriaxone exerts antitumor effects in MYCN-driven retinoblastoma and neuroblastoma by targeting DDX3X for translation repression. Article Snippet: Immunoprecipitation Cells were treated with 25 lM MG132 (Millipore) in methionine-free RPMI-1640 supplemented with 200 lM L-HPG for 2 h and lysed using immunoprecipitation lysis buffer (25 mM Tris–HCl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, and 5% glycerol) containing protease and phosphatase inhibitors. .. The protein was collected and incubated with |